These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 476270)

  • 1. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined immunotherapy of malignant melanoma. Unusual survival following cerebral metastasis.
    Spitler LE; Wong P; Sagebiel R
    Arch Dermatol; 1978 Oct; 114(10):1501-4. PubMed ID: 718187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
    Knopf B; Wätzig V; Knöll B
    Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological factors which influence response to immunotherapy in malignant melanoma.
    Morton D; Eilber FR; Malmgren RA; Wood WC
    Surgery; 1970 Jul; 68(1):158-63; discussion 163-4. PubMed ID: 10483463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations in immunotherapy of lymphoma and melanoma patients.
    Thomas JW; Plenderleith IH; Clements DV; Landi S
    Clin Exp Immunol; 1975 Jul; 21(1):82-96. PubMed ID: 1102163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immune profil in melanoma patients. III. Behavior of immunglobulins (IgG, IgA, IgM) and of whole complement in serum at the beginning and during BCG-therapy (author's transl)].
    Knopf B; Wätzig V; Stelzner A
    Arch Geschwulstforsch; 1979; 49(4):299-304. PubMed ID: 496567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC; Cosimi AB; Carey RW; Kaufman SD
    Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients.
    Buckley CE; White DH; Seigler HF
    Monogr Allergy; 1977; 11():97-105. PubMed ID: 876133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
    Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
    Wile AG; Sparks FC; Morton DL
    Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intrafocal BCG therapy of metastasizing malignant melanoma].
    Kunze J; Lesch R; Plagwitz R; Hagedorn M
    Hautarzt; 1978 Nov; 29(11):597-600. PubMed ID: 721465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.